The Scleroderma Research Foundation was proud to participate as a Strategic Collaborator in the inaugural meeting of Vie Ventures’ Therapeutics Advisory Council (TAC), held September 9 in New York City. This new coalition brings together leading disease foundations, investors, and industry experts to accelerate therapies for autoimmune and inflammatory diseases.
As SRF Chairman Luke Evnin, PhD, noted, the TAC “demonstrated the value of bringing foundations together with industry and venture capital to accelerate progress in autoimmune disease.”
The first scientific session focused on fibrosis, a common pathway across many autoimmune conditions, underscoring the importance of cross-disease collaboration in tackling shared challenges such as biomarkers, trial design, and regulatory hurdles.
By uniting philanthropy, science, and venture capital, the TAC represents an innovative model to speed the development of breakthrough treatments—work that directly aligns with the SRF’s laser-focused research mission to facilitate improved therapies and, ultimately, a cure for scleroderma.
The SRF is honored to stand alongside these other leading disease foundations who are participating as Strategic Collaborators: American Diabetes Association, Arthritis Foundation, Beyond Celiac, Crohn’s & Colitis Foundation, Food Allergy Fund, Immune Boost Capital, Lupus Research Alliance, National Multiple Sclerosis Society, National Psoriasis Foundation, and Sjögren’s Foundation.
